Analysts Set Privia Health Group, Inc. (NASDAQ:PRVA) Target Price at $25.19

Privia Health Group, Inc. (NASDAQ:PRVA) has received an average rating of “Buy” from the sixteen analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $26.47.

A number of equities analysts have recently weighed in on the company. Canaccord Genuity Group boosted their target price on Privia Health Group from $29.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday. JMP Securities restated a “market outperform” rating and issued a $26.00 target price on shares of Privia Health Group in a research note on Friday, February 14th. Barclays boosted their target price on Privia Health Group from $19.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Friday, November 8th. Truist Financial boosted their target price on Privia Health Group from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Finally, Piper Sandler lifted their price target on shares of Privia Health Group from $25.00 to $40.00 and gave the stock an “overweight” rating in a report on Friday.

Privia Health Group Stock Down 1.9 %

Shares of NASDAQ PRVA opened at $24.97 on Thursday. Privia Health Group has a twelve month low of $15.92 and a twelve month high of $26.04. The stock’s 50 day moving average price is $22.40 and its 200-day moving average price is $20.60. The company has a market capitalization of $3.00 billion, a PE ratio of 249.72, a PEG ratio of 3.47 and a beta of 0.87.

Institutional Investors Weigh In On Privia Health Group

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Mackenzie Financial Corp raised its holdings in Privia Health Group by 87.2% during the 4th quarter. Mackenzie Financial Corp now owns 72,391 shares of the company’s stock valued at $1,415,000 after acquiring an additional 33,728 shares during the period. Neo Ivy Capital Management grew its position in shares of Privia Health Group by 81.5% during the 4th quarter. Neo Ivy Capital Management now owns 6,540 shares of the company’s stock valued at $127,000 after purchasing an additional 2,936 shares in the last quarter. PharVision Advisers LLC purchased a new position in shares of Privia Health Group during the 4th quarter valued at $259,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Privia Health Group by 13.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 939,170 shares of the company’s stock valued at $18,361,000 after purchasing an additional 114,647 shares in the last quarter. Finally, Two Sigma Advisers LP purchased a new position in shares of Privia Health Group during the 4th quarter valued at $940,000. Institutional investors own 94.48% of the company’s stock.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.